<SEC-DOCUMENT>0001558370-21-006991.txt : 20210513
<SEC-HEADER>0001558370-21-006991.hdr.sgml : 20210513
<ACCEPTANCE-DATETIME>20210513073027
ACCESSION NUMBER:		0001558370-21-006991
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210513
FILED AS OF DATE:		20210513
DATE AS OF CHANGE:		20210513

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Evaxion Biotech A/S
		CENTRAL INDEX KEY:			0001828253
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			G7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39950
		FILM NUMBER:		21917198

	BUSINESS ADDRESS:	
		STREET 1:		BREDGADE 34E
		CITY:			COPENHAGEN K
		STATE:			G7
		ZIP:			1260
		BUSINESS PHONE:		4531262615

	MAIL ADDRESS:	
		STREET 1:		BREDGADE 34E
		CITY:			COPENHAGEN K
		STATE:			G7
		ZIP:			1260
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>tmb-20210513x6k.htm
<DESCRIPTION>6-K
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.10.0.88--><!--Created on: 5/13/2021 11:30:20 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:1pt;text-align:center;border-top:3.0pt solid #000000;margin:0pt;"><font style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:1pt;text-align:center;border-top:1.0pt solid #000000;margin:0pt;"><font style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:16pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:16pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Washington, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:12pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:16pt;font-weight:bold;">FORM&#160;6-K</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:12pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">REPORT OF FOREIGN PRIVATE ISSUER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PURSUANT TO SECTION&#160;13a-16 OR 15d-16</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">UNDER THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">For the&#160;month of May&#160;2021</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Commission File Number: 001-39950</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:12pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><b style="font-size:22pt;font-weight:bold;">Evaxion Biotech A/S</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Exact Name of Registrant as Specified in Its Charter)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:12pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dr.&#160;Neergaards Vej 5f</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">DK-2970 Hoersholm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Denmark</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:12pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form&#160;20-F or Form&#160;40-F.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 206pt;">Form&#160;20-F &#9746;<font style="display:inline-block;width:26.44pt;"></font>Form&#160;40-F &#9744;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation S-T Rule&#160;101(b)(1): &#9744;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation S-T Rule&#160;101(b)(7): &#9744;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1.0pt solid #000000;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:3.0pt solid #000000;margin:0pt 0pt 12pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Furnished as Exhibit&#160;99.1 to this Report on Form&#160;6-K is a press release of Evaxion Biotech A/S (the &#8220;Company&#8221;) dated May&#160;13, 2021, announcing the Company&#8217;s financial results for the three&#160;months ended March&#160;31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Exhibits</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:88.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Exhibit</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:88.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:8.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">No.</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:88.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Description</p></td></tr><tr><td style="vertical-align:bottom;width:8.33%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:88.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">99.1</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:88.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="tmb-20210513xex99d1.htm"><font style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:left;">Press Release dated May</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:left;">&#160;</font><font style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:left;">13, 2021.</font></a></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Evaxion Biotech A/S</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May&#160;13, 2021</p></td><td style="vertical-align:bottom;width:4.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:45.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Glenn S. Vraniak</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Glenn S. Vraniak</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tmb-20210513xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.10.0.88--><!--Created on: 5/13/2021 11:30:17 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;text-align:right;margin:0pt 0pt 6pt 0pt;"><img src="tmb-20210513xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:63.36pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:148.3pt;"></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-weight:bold;text-align:right;margin:12pt 0pt 12pt 0pt;">Exhibit&#160;99.1</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-weight:bold;margin:12pt 0pt 12pt 0pt;">Evaxion Biotech Announces Q1 2021 Financial Results and Provides Business Update</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">Raised net proceeds of $27.9 million in U.S. initial public offering in February&#160;2021</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">Lead programs EVX-01 and EVX-02 on track for Phase 1/2a data readouts late in Q2</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">Product candidates EVX-03 and EVX-B1 progressing through pre-clinical development</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">Cash reserves of $27 million at March&#160;31, 2021</font></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Copenhagen, Denmark, May&#160;13, 2021</b>&#160;&#8211; Evaxion Biotech A/S (NASDAQ: EVAX) (&#8220;Evaxion&#8221; or the &#8220;Company&#8221;), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer, bacterial diseases and viral infections, announced today the first quarter 2021 financial results and provided an operational update.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Lars Wegner, CEO of Evaxion</b>, said: &#8220;Evaxion made strong progress in Q1 2021, successfully concluding our U.S. IPO and continuing to advance our clinical programs. Our two lead product candidates, EVX-01 and EVX-02, are on track for results from Phase 1/2a trials late in Q2 and we continue to develop our RAVEN AI platform for vaccine design and development for viral infections. We believe that our cash reserves of $27 million provide a solid financial foundation and will facilitate the continued development of our four lead programs.&#8221;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;margin:12pt 0pt 12pt 0pt;">Operational and Business Highlights in Q1 2021</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">Closed U.S. initial public offering of 3,000,000 American Depositary Shares at a public offering price of $10.00 per ADS. The gross proceeds from the offering, before deducting underwriting fees and commissions and other offering expenses, were $30 million.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">Recruitment for two lead product candidates, EVX-01 and EVX-02, in Phase 1/2a clinical trials remains on track for data readouts late in Q2.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">Other lead product candidates, EVX-03 for multiple cancer indications and EVX-B1, a vaccine for the prevention of </font><i style="color:#000000;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:italic;font-weight:normal;text-align:left;">Staphylococcus aureus</i><font style="color:#000000;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;"> including MRSA, continue to progress as expected through pre-clinical development and Chemistry, Manufacturing and Controls (CMC).</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">Cash reserves at March&#160;31, 2021 of $27.0 million, provide continued funding of key programs.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">Opened new corporate headquarters and research laboratory facility located in the DTU Science Park in Hoersholm near Copenhagen, Denmark.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">Publication of a paper in the peer-reviewed journal Scientific Reports, describing a study into the bacterium </font><i style="color:#000000;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:italic;font-weight:normal;text-align:left;">S. aureus</i><font style="color:#000000;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">, which may facilitate a better understanding of host-pathogen interactions during invasive infection.</font></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;margin:12pt 0pt 12pt 0pt;">Events after the Reporting Period</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">Presentation at the 4th Neoantigen Summit Europe, described Evaxion&#8217;s recent improvement in determining cancer neoepitopes through measurement and prediction of peptide-MHC (pMHC) complex stability.</font></td></tr></table><div style="margin-top:6pt;"></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Expected milestones in 2021</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">Phase 1/2a data readout on EVX-01 in metastatic melanoma&#160;- Q2 2021</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">Phase 1/2a data readout on EVX-02 in adjuvant melanoma&#160;- Q2 2021</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">Regulatory filing for clinical trial of EVX-03 in multiple cancers&#160;- H2 2021</font></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;margin:12pt 0pt 12pt 0pt;">First Quarter 2021 Financial Results</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#444444;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><u style="color:#444444;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;text-decoration:underline;text-decoration-color:#444444;">Cash position</u><font style="color:#444444;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">: As of March&#160;31, 2021, cash and cash equivalents were $27.0 million compared to $5.8 million as of December&#160;31, 2020. On February&#160;9, 2021, we closed our IPO raising net proceeds of $27.9 million after underwriting discounts and commissions, but before offering expenses.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#444444;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><u style="color:#444444;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;text-decoration:underline;text-decoration-color:#444444;">Research and Development expenses</u><font style="color:#444444;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;"> were $3.9 million for the quarter ended March&#160;31, 2021, compared to $2.5 million for the same period in 2020. </font><font style="color:#444444;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">The increase of $1.4 million was primarily related to </font><font style="color:#444444;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">increased spending, net of grant income, for ongoing development on our platform, pre-clinical product candidates, and clinical trials. In addition, employee-related costs increased due to higher headcount.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#444444;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><u style="color:#444444;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;text-decoration:underline;text-decoration-color:#444444;">General and Administrative expenses</u><font style="color:#444444;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;"> were $1.3 million for the quarter ended March&#160;31, 2021, compared to $0.8 million for the same period in 2020. </font><font style="color:#444444;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">The increase of $0.5 million was primarily related to </font><font style="color:#444444;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">increases in overhead and professional fees related to the expansion of our corporate function for our initial public offering.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#444444;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><u style="color:#444444;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;text-decoration:underline;text-decoration-color:#444444;">Net loss</u><font style="color:#444444;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;"> was $4.1 million for the quarter ended March&#160;31, 2021 or ($0.23) loss per basic and diluted share, compared to $3.1 million, or ($0.20) loss per basic and diluted share, for the same period in 2020.</font></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:italic;margin:12pt 0pt 12pt 0pt;">Guidance</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#444444;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#444444;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">Evaxion&#8217;s operating plan extends its cash runway into 2022.</font></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;margin:12pt 0pt 12pt 0pt;">Webcast and Conference Call</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt 0pt 6pt 0pt;">Evaxion will host a webcast and conference call today, May&#160;13, at 8:30&#160;a.m. EDT.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt 0pt 6pt 0pt;">To dial-in for the conference call, please use the following details:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt 0pt 6pt 0pt;">US: 877-407-0792</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt 0pt 6pt 0pt;">International: +1-201-689-8263</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt 0pt 6pt 0pt;">Conference ID: 13718732</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt 0pt 6pt 0pt;">Alternatively to access the audio webcast, please visit the events page&#160;of Evaxion&#8217;s website at:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt 0pt 6pt 0pt;">https://evaxion-biotech.com/news-and-events/events/default.aspx</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;margin:12pt 0pt 12pt 0pt;">About Evaxion</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt 0pt 6pt 0pt;">Evaxion Biotech A/S is a clinical-stage AI-immunology&#8482; platform company decoding the human immune system to discover and develop novel immunotherapies to treat cancer, bacterial diseases and viral infections. Based on its proprietary and scalable AI-immunology core technology, Evaxion is developing a broad pipeline of novel product candidates which currently includes three patient-specific cancer immunotherapies, two of which are in Phase 1/2a clinical development. In addition, Evaxion is advancing a portfolio of vaccines to prevent bacterial and viral infections currently in preclinical development.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">For more information</b></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:59.61%;"><tr style="height:1pt;"><td style="vertical-align:top;width:44.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:7.17%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:48.47%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:44.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;">Evaxion</p></td><td style="vertical-align:top;width:7.17%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:48.47%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;">LifeSci Advisors LLC</p></td></tr><tr><td style="vertical-align:top;width:44.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;">Glenn S. Vraniak</p></td><td style="vertical-align:top;width:7.17%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="margin-bottom:6pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.47%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;">Mary-Ann Chang</p></td></tr><tr><td style="vertical-align:top;width:44.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;">Chief Financial Officer</p></td><td style="vertical-align:top;width:7.17%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="margin-bottom:6pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.47%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;">Managing Director</p></td></tr><tr><td style="vertical-align:top;width:44.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;">gvr@evaxion-biotech.com</p></td><td style="vertical-align:top;width:7.17%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="margin-bottom:6pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.47%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;">mchang@lifesciadvisors.com</p></td></tr><tr><td style="vertical-align:top;width:44.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;">+1 (513) 476-2669</p></td><td style="vertical-align:top;width:7.17%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="margin-bottom:6pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.47%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;">+44 7483 284 853</p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt 0pt 6pt 0pt;">Source: Evaxion Biotech</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Forward-looking statement</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt 0pt 6pt 0pt;">This announcement contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this announcement regarding the Company&#8217;s future operations, plans and objectives are forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this announcement about future events are subject to (i)&#160;change without notice and (ii)&#160;factors beyond the Company&#8217;s control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as &#8220;target,&#8221; &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;hope,&#8221; &#8220;aim,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;anticipate,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;estimate,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;will,&#8221; &#8220;can have,&#8221; &#8220;likely,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;could&#8221;, and other words and terms of similar meaning or the negative thereof. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including but not limited to: risks associated with the Company&#8217;s financial condition and need for additional capital; risks associated with the Company&#8217;s development work; cost and success of the Company&#8217;s product development activities and preclinical and clinical trials; risks related to commercializing any approved pharmaceutical product developed using the Company&#8217;s AI platform technology, including the rate and degree of market acceptance of the Company&#8217;s product candidates; risks related to the Company&#8217;s dependence on third parties including for conduct of clinical testing and product manufacture; risks associated with the Company&#8217;s inability to enter into partnerships; risks related to government regulation; risks associated with protection of the Company&#8217;s intellectual property rights; risks related to employee matters and managing growth; risks related to the Company&#8217;s ADSs and ordinary shares, risks associated with the pandemic caused by the coronavirus known as COVID-19 and other risks and uncertainties affecting the Company&#8217;s business operations and financial condition.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt 0pt 6pt 0pt;">Forward-looking statements are subject to inherent risks and uncertainties beyond the Company&#8217;s control that could cause the Company&#8217;s actual results, performance, or achievements to be materially different from the expected results, performance, or achievements expressed or implied by such forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company&#8217;s business in general, see the risks described in the &#8220;Risk Factors&#8221; section included in the Company&#8217;s Form 20-F for the year ended December 31, 2020 and the Company&#8217;s other reports filed with, or submitted to, the U.S. Securities and Exchange Commission (SEC). Any forward-looking statements contained in this announcement speak only as of the date hereof, and except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Evaxion Biotech A/S</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Consolidated Statements of Financial Position Data (Unaudited)</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:8.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:7.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:3pt 0pt 0pt 6pt;">Cash and cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:8.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:3pt 3pt 0pt 0pt;">26,955</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:3pt 3pt 0pt 0pt;">5,834</p></td></tr><tr><td style="vertical-align:bottom;width:76.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:3pt 0pt 0pt 6pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.3%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:8.78%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:3pt 3pt 0pt 0pt;">34,920</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.16%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:7.94%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:3pt 3pt 0pt 0pt;">11,965</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:3pt 0pt 0pt 6pt;">Total liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.3%;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:8.78%;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:3pt 3pt 0pt 0pt;">7,121</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.16%;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:7.94%;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:3pt 3pt 0pt 0pt;">4,927</p></td></tr><tr><td style="vertical-align:bottom;width:76.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:3pt 0pt 0pt 6pt;">Share capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.3%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:8.78%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:3pt 3pt 0pt 0pt;">3,132</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:7.94%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:3pt 3pt 0pt 0pt;">2,648</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:3pt 0pt 0pt 6pt;">Other reserves</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:8.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:3pt 3pt 0pt 0pt;">55,745</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:3pt 3pt 0pt 0pt;">31,669</p></td></tr><tr><td style="vertical-align:bottom;width:76.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:3pt 0pt 0pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:8.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:3pt 0pt 0pt 0pt;">(31,078)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:3pt 0pt 0pt 0pt;">(27,279)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:3pt 0pt 0pt 6pt;">Total equity</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.3%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:8.78%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:3pt 3pt 0pt 0pt;">27,799</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.16%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:7.94%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:3pt 3pt 0pt 0pt;">7,038</p></td></tr><tr><td style="vertical-align:bottom;width:76.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:3pt 0pt 0pt 6pt;">Total liabilities and equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.3%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;">$</p></td><td style="vertical-align:bottom;width:8.78%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:3pt 0pt 0pt 0pt;">34,920&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.16%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;">$</p></td><td style="vertical-align:bottom;width:7.94%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:3pt 0pt 0pt 0pt;">11,965&#160;</p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Evaxion Biotech A/S</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Consolidated Statements of Comprehensive Loss Data (Unaudited)</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">(USD in thousands, except per share data)</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:26.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;Ended&#160;March&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:12.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:12.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:3pt 0pt 0pt 6pt;">Research and development expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:11.11%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:3pt 3pt 0pt 0pt;">3,893</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:11.11%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:3pt 3pt 0pt 0pt;">2,510</p></td></tr><tr><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:3pt 0pt 0pt 6pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:3pt 3pt 0pt 0pt;">1,282</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:3pt 3pt 0pt 0pt;">781</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:3pt 0pt 0pt 6pt;">Operating loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:11.11%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:3pt 0pt 0pt 0pt;">(5,175)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:11.11%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:3pt 0pt 0pt 0pt;">(3,291)</p></td></tr><tr><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:3pt 0pt 0pt 6pt;">Finance income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:3pt 3pt 0pt 0pt;">972</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:3pt 3pt 0pt 0pt;">16</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:3pt 0pt 0pt 6pt;">Finance expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:3pt 0pt 0pt 0pt;">(297)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:3pt 0pt 0pt 0pt;">(4)</p></td></tr><tr><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:3pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Net loss before tax</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:11.11%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:3pt 0pt 0pt 0pt;">(4,500)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:11.11%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:3pt 0pt 0pt 0pt;">(3,279)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:3pt 0pt 0pt 6pt;">Income taxes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:3pt 3pt 0pt 0pt;">407</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:3pt 3pt 0pt 0pt;">180</p></td></tr><tr><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:3pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Net loss for the period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;">$</p></td><td style="vertical-align:bottom;width:11.11%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:3pt 0pt 0pt 0pt;">(4,093)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;">$</p></td><td style="vertical-align:bottom;width:11.11%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:3pt 0pt 0pt 0pt;">(3,099)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:3pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Net loss attributable to equity holders of Evaxion Biotech A/S</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:3pt 0pt 0pt 0pt;">(4,093)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:3pt 0pt 0pt 0pt;">(3,099)</p></td></tr><tr><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:3pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Loss per share &#8211; basic and diluted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;">$</p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:3pt 0pt 0pt 0pt;">(0.23)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;">$</p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:3pt 0pt 0pt 0pt;">(0.20)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:3pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Number of shares used for calculation (basic and diluted)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:3pt 3pt 0pt 0pt;">17,865,335</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:3pt 3pt 0pt 0pt;">15,184,152</p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tmb-20210513xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20210513xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !_ 2D# 2(  A$! Q$!_\0
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F444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
